LPOXY’s plan is to take Sidiprev into a phase 2 study in hospitalized patients with Clostridioides difficile infection. Known as one of the superbugs that resists most antibiotics, C.
Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback